A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Labcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world. In addition, the Company provided support for more than 85% of the new drugs and therapeutic products approved in 2025 by the FDA. The Company’s strength in science, technology, and innovation, as well as its global scale, powers its continued success, differentiates the Company, and enables it to play a leading role in advancing healthcare across the globe.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 14.0B | 14.0B | 13.0B | 12.2B | 11.9B | 16.1B |
| Net Income | 877M | 877M | 746M | 418M | 1.3B | 2.4B |
| EPS | $10.46 | $10.46 | $8.84 | $4.77 | $12.00 | $12.00 |
| Free Cash Flow | 1.2B | 1.2B | 1.1B | 874M | 1.5B | 2.6B |
| ROIC | 7.5% | 6.5% | 5.3% | 3.2% | 7.6% | 14.1% |
| Gross Margin | 28.8% | 28.8% | 27.9% | 27.7% | 31.3% | 34.9% |
| Debt/Equity | 0.75 | 0.75 | 0.89 | 0.87 | 0.64 | 0.64 |
| Dividends/Share | $2.87 | $2.88 | $2.88 | $2.90 | $1.83 | $0.99 |
| Operating Income | 1.4B | 1.4B | 1.1B | 726M | 1.4B | 3.3B |
| Operating Margin | 9.9% | 9.9% | 8.4% | 6.0% | 12.1% | 20.2% |
| ROE | 10.2% | 10.5% | 9.3% | 5.3% | 12.7% | 23.1% |
| Shares Outstanding | 84M | 84M | 84M | 88M | 107M | 198M |
LABCORP HOLDINGS INC. passes 4 of 9 quality checks, suggesting mixed fundamentals.
LABCORP HOLDINGS INC. trades at 25.3x trailing earnings, compared to its 15-year median P/E of 15.8x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 18.1x vs a median of 14.5x. The company's 5-year average ROIC is 7.4% with a gross margin of 30.1%. Total shareholder yield (dividends + buybacks) is 3.1%. At current prices, the estimated annualized return to fair value is +3.8%.
LABCORP HOLDINGS INC. (LH) has a current P/E ratio of 25.3, compared to its historical median P/E of 15.8. The stock is currently considered Fair based on its historical valuation range.
LABCORP HOLDINGS INC. (LH) has a 5-year average return on invested capital (ROIC) of 7.4%. This is below average and may indicate limited pricing power.
LABCORP HOLDINGS INC. (LH) has a market capitalization of $22.1B. It is classified as a large-cap stock.
Yes, LABCORP HOLDINGS INC. (LH) pays a dividend with a trailing twelve-month yield of 1.09%. The company also returns capital through share buybacks, with a buyback yield of 2.03%.
Based on historical P/E analysis, LABCORP HOLDINGS INC. (LH) appears fair. The current P/E of 25.3 is 60% above its historical median of 15.8. The estimated fair value CAGR (P/E method) is 8.3%.
LABCORP HOLDINGS INC. (LH) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
LABCORP HOLDINGS INC. (LH) reported annual revenue of $14.0 billion in its most recent fiscal year, based on SEC EDGAR filings.
LABCORP HOLDINGS INC. (LH) has a net profit margin of 6.3%. This is a modest margin.
LABCORP HOLDINGS INC. (LH) generated $1.2 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
LABCORP HOLDINGS INC. (LH) has a debt-to-equity ratio of 0.75. This indicates moderate leverage.
LABCORP HOLDINGS INC. (LH) reported earnings per share (EPS) of $10.46 in its most recent fiscal year.
LABCORP HOLDINGS INC. (LH) has a return on equity (ROE) of 10.5%. This indicates moderate shareholder returns.
LABCORP HOLDINGS INC. (LH) has a 5-year average gross margin of 30.1%. This indicates decent pricing power.
The Ledger Terminal provides 19 years of financial data for LABCORP HOLDINGS INC. (LH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LABCORP HOLDINGS INC. (LH) has a book value per share of $102.87, based on its most recent annual SEC filing.